Literature DB >> 9109433

Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus.

A Kretz-Rommel1, S R Duncan, R L Rubin.   

Abstract

A side effect of therapy with procainamide and numerous other medications is a lupus-like syndrome characterized by autoantibodies directed against denatured DNA and the (H2A-H2B)-DNA subunit of chromatin. We tested the possibility that an effect of lupus-inducing drugs on central T cell tolerance underlies these phenomena. Two intrathymic injections of procainamide-hydroxylamine (PAHA), a reactive metabolite of procainamide, resulted in prompt production of IgM antidenatured DNA antibodies in C57BL/6xDBA/2 F1 mice. Subsequently, IgG antichromatin antibodies began to appear in the serum 3 wk after the second injection and were sustained for several months. Specificity, inhibition and blocking studies demonstrated that the PAHA-induced antibodies showed remarkable specificity to the (H2A-H2B)-DNA complex. No evidence for polyclonal B cell activation could be detected based on enumeration of Ig-secreting B cells and serum Ig levels, suggesting that a clonally restricted autoimmune response was induced by intrathymic PAHA. The IgG isotype of the antichromatin antibodies indicated involvement of T cell help, and proliferative responses of splenocytes to oligonucleosomes increased up to 100-fold. As little as 5 microM PAHA led to a 10-fold T cell proliferative response to chromatin in short term organ culture of neonatal thymi. We suggest that PAHA interferes with self-tolerance mechanisms accompanying T cell maturation in the thymus, resulting in the emergence of chromatin-reactive T cells followed by humoral autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9109433      PMCID: PMC508013          DOI: 10.1172/JCI119356

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  62 in total

1.  V beta gene repertoires in aging mice.

Authors:  R González-Quintial; A N Theofilopoulos
Journal:  J Immunol       Date:  1992-07-01       Impact factor: 5.422

2.  Isotype-restricted hyperimmunity in a murine model of the toxic oil syndrome.

Authors:  S A Bell; M V Hobbs; R L Rubin
Journal:  J Immunol       Date:  1992-06-01       Impact factor: 5.422

3.  Kinetic analysis of deoxyribonuclease I cleavages in the nucleosome core: evidence for a DNA superhelix.

Authors:  L C Lutter
Journal:  J Mol Biol       Date:  1978-09-15       Impact factor: 5.469

Review 4.  Positive selection of thymocytes.

Authors:  S C Jameson; K A Hogquist; M J Bevan
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

5.  A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells.

Authors:  J D Sedgwick; P G Holt
Journal:  J Immunol Methods       Date:  1983-02-25       Impact factor: 2.303

6.  A systemic lupus erythematosus (SLE)-like disease in mice induced by abnormal T-B cell cooperation. Preferential formation of autoantibodies characteristic of SLE.

Authors:  E Gleichmann; E H Van Elven; J P Van der Veen
Journal:  Eur J Immunol       Date:  1982-02       Impact factor: 5.532

7.  Intermittent intravenous procaine amide to treat ventricular arrhythmias. Correlation of plasma concentration with effect on arrhythmia, electrocardiogram, and blood pressure.

Authors:  E G Giardina; R H Heissenbuttel; J T Bigger
Journal:  Ann Intern Med       Date:  1973-02       Impact factor: 25.391

8.  T-cell maturation and clonal deletion in cyclosporine-induced autoimmunity.

Authors:  G J Prud'homme; R Sanders; N A Parfrey; H Ste-Croix
Journal:  J Autoimmun       Date:  1991-04       Impact factor: 7.094

9.  Generation and analysis of interleukin-4 deficient mice.

Authors:  R Kühn; K Rajewsky; W Müller
Journal:  Science       Date:  1991-11-01       Impact factor: 47.728

10.  Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide.

Authors:  J P Uetrecht
Journal:  J Pharmacol Exp Ther       Date:  1985-02       Impact factor: 4.030

View more
  9 in total

Review 1.  Drug-induced lupus erythematosus: incidence, management and prevention.

Authors:  Christopher Chang; M Eric Gershwin
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

Review 2.  Autoreactive T cells in murine lupus: origins and roles in autoantibody production.

Authors:  J Craft; S Peng; T Fujii; M Okada; S Fatenejad
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 3.  Drug-induced lupus erythematosus: an update on drugs and mechanisms.

Authors:  Ye He; Amr H Sawalha
Journal:  Curr Opin Rheumatol       Date:  2018-09       Impact factor: 5.006

4.  Genetic dissection of lupus pathogenesis: a recipe for nephrophilic autoantibodies.

Authors:  C Mohan; L Morel; P Yang; H Watanabe; B Croker; G Gilkeson; E K Wakeland
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

5.  A female preponderance for chemically induced lupus in SJL/J mice.

Authors:  Deborah L Smith; Xin Dong; Sienmi Du; Myungshin Oh; Ram Raj Singh; Rhonda R Voskuhl
Journal:  Clin Immunol       Date:  2006-11-01       Impact factor: 3.969

Review 6.  Environmentally induced autoimmune diseases: potential mechanisms.

Authors:  T Rao; B Richardson
Journal:  Environ Health Perspect       Date:  1999-10       Impact factor: 9.031

Review 7.  Initiation of autoimmunity by a reactive metabolite of a lupus-inducing drug in the thymus.

Authors:  R L Rubin; A Kretz-Rommel
Journal:  Environ Health Perspect       Date:  1999-10       Impact factor: 9.031

8.  Autoreactive B cells recruited to lungs by silica exposure contribute to local autoantibody production in autoimmune-prone BXSB and B cell receptor transgenic mice.

Authors:  Lanette Fee; Advika Kumar; Robert M Tighe; Mary H Foster
Journal:  Front Immunol       Date:  2022-08-02       Impact factor: 8.786

9.  Machine Learning for Predicting Risk of Drug-Induced Autoimmune Diseases by Structural Alerts and Daily Dose.

Authors:  Yue Wu; Jieqiang Zhu; Peter Fu; Weida Tong; Huixiao Hong; Minjun Chen
Journal:  Int J Environ Res Public Health       Date:  2021-07-03       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.